Syndax collaborates with Incyte to develop monoclonal antibody
The antibody will be developed to treat chronic graft-versus-host disease and other immune-mediated diseases.
Immunology
AzurRx BioPharma to acquire First Wave Bio for $229m
AzurRx’s management team comprising CEO James Sapirstein will remain in the role to lead the...
Lilly collaborates with Lycia to develop new LYTAC degraders
The partnership plans to develop new degraders for up to five targets in Lilly’s focus...
BMS to in-license Exscientia’s AI-driven drug candidate
An option exercise fee of $20m will be paid to Exscientia by BMS, which will...
GentiBio raises $157m to develop Treg therapies for autoimmune diseases
The proceeds will be used to advance the company’s Treg therapy for type 1 diabetes...
Bayer to acquire Vividion for $1.5bn to boost drug discovery platform
Vividion will leverage Bayer’s experience, infrastructure and reach to autonomously develop its technology and portfolio.
ViiV Healthcare and Halozyme partner to develop long-acting HIV therapies
ViiV Healthcare and Halozyme plan to start experiments with ENHANZE by year-end for the drug cabotegravir for HIV prevention.
Umoja Biopharma raises $210m to advance next-gen cancer immunotherapy technology
The company is building an integrated cellular immunotherapy platform to reprogramme immune cells in vivo.
HiFiBiO raises series D funds to advance immuno-oncology candidates
HiFiBiO Therapeutics plans to accelerate two immuno-oncology programmes and to validate its Drug Intelligent Science platform in clinical trials.
UK CMA launches inquiry into $39bn AstraZeneca and Alexion merger
The UK Competition and Markets Authority started enquiring into the AstraZeneca proposed Alexion acquisition for $39bn.
Exscientia signs $1.2bn AI drug discovery deal with BMS
Bristol-Myers Squibb and Exscientia enter a partnership agreement to discover small molecule drug candidates using AI.
